NCT06356025View on ClinicalTrials.gov

Botulinum Toxin Injection in the UES for R-CPD

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Retrograde Cricopharyngeus Dysfunction
Interventions
DRUG

botulinum toxin type A

Botulinum toxin type A 75U dissolved in 3mL physiological serum injection in the upper esophageal sphincter

DRUG

Sodium Chloride 0.9% Inj

Placebo: physiological serum 3mL injection in the upper esophageal sphincter

Trial Locations (1)

Unknown

RECRUITING

AZ Delta, Roeselare

Sponsors

Lead Sponsor

AZ Delta
All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

AZ Delta

OTHER